Press Releases
At Pulmatrix, we are committed to communicating clear and consistent information. Here we feature current and historic content concerning our science, our pipeline, and our corporate initiatives and achievements. Please check in often for the most recent press releases and information.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Mar 14, 2019Pulmatrix, Inc. (NASDAQ: PULM) announced today that members of its management team will present/participate in investor meetings at the following upcoming conferences: Oppenheimer's 29th Annual...
- Mar 12, 2019
Pulmatrix, Inc. (NASDAQ: PULM) announced today that it received a letter from the listing qualifications department staff of The NASDAQ Stock Market LLC, stating that the Company has regained...
- Feb 19, 2019
Pulmatrix, Inc. (NASDAQ: PULM) today announces 2018 financial results, reviews the Company's recent progress, and provides an outlook for its pulmonary disease development pipeline. "The funds...
- Feb 12, 2019PUR1800 (1 US Patent) and PUR5700 (2 US Patents and 2 EU Patents) Intellectual Property Portfolio Expands Significantly
Pulmatrix, Inc. (NASDAQ: PULM) has been awarded five new patents that expand the intellectual property protection for Pulmatrix's PUR1800 and PUR5700 programs. These patents expand the...
- Feb 8, 2019
Pulmatrix, Inc. ("Pulmatrix," the "Company," "we," "our" or "us") (NASDAQ: PULM) today announced that it has entered into a securities purchase agreement with certain institutional investors,...
- Feb 7, 2019Pulmatrix notified of FDA's authorization to proceed for a Phase 2 study of Pulmazole (inhaled itraconazole) in asthmatic patients with allergic bronchopulmonary aspergillosis (ABPA)
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company focused on developing novel inhaled therapeutics to serve unmet needs in respiratory disease, announced today that the US...
- Feb 6, 2019Files Withdrawal of Registration Statement with the SEC
Pulmatrix, Inc. ("Pulmatrix," the "Company," "we," "our" or "us") (NASDAQ: PULM) today announced the termination of its previously planned underwritten public offering, with Oppenheimer & Co.,...
- Feb 5, 2019
Pulmatrix, Inc. ("Pulmatrix," the "Company," "we," "our" or "us") (NASDAQ: PULM) today announced a 1-for-10 reverse split of its common stock, effective as of 5:00 pm Eastern Time, February 5,...
- Feb 5, 2019
Pulmatrix, Inc. ("Pulmatrix," the "Company," "we," "our" or "us") (NASDAQ: PULM) today announced the closing and funding of its previously announced underwritten public offering of 5,323,530...
- Jan 31, 2019
Pulmatrix, Inc. ("Pulmatrix," the "Company," "we," "our" or "us") (NASDAQ: PULM) today announced the closing and funding of its previously announced underwritten public offering of 1,561,177...
- Jan 30, 2019
Pulmatrix, Inc. ("Pulmatrix," the "Company," "we," "our" or "us") (NASDAQ: PULM) today announced the pricing of an underwritten public offering of 5,323,530 shares of its common stock at a price...
- Jan 30, 2019
LEXINGTON, Mass., Jan. 30, 2019 /PRNewswire/ – Pulmatrix, Inc. ("Pulmatrix," the "Company," "we," "our" or "us") (NASDAQ: PULM) today announced that it intends to offer and sell, subject to...
- Jan 28, 2019
Pulmatrix, Inc. ("Pulmatrix," the "Company," "we," "our" or "us") (NASDAQ: PULM) today announced the pricing of an underwritten public offering of 1,561,177 shares of its common stock at a price...
- Jan 28, 2019
Pulmatrix, Inc. ("Pulmatrix," the "Company," "we," "our" or "us") (NASDAQ: PULM) today announced that it intends to offer and sell, subject to market and other conditions, shares of its common...
- Nov 29, 2018
Pulmatrix, Inc. ("Pulmatrix," the "Company," "we," "our" or "us") (NASDAQ: PULM) today announced that it has entered into a securities purchase agreement with an institutional investor, providing...
- Nov 21, 2018All objectives from the Phase 1/1b study successfully met, on track to initiate a Phase 2 study in asthmatic patients with allergic bronchopulmonary aspergillosis (ABPA) in 2018
Pulmatrix, Inc. (NASDAQ: PULM) announced the results of the completed first-in-human study of Pulmazole (PUR1900) — an inhaled iSPERSETM formulation of the anti-fungal drug itraconazole for the...
- Nov 15, 2018
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases will present the results of the recently...
- Nov 14, 2018
Pulmatrix, Inc. (NASDAQ: PULM) today reported its third quarter results. "We remain focused on advancing the clinical development of our Pulmazole program," said Robert W. Clarke, Ph.D., chief...
- Sep 17, 2018
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases will present preclinical data on the...
- Aug 28, 2018
Pulmatrix, Inc. (NASDAQ: PULM) will present at the Rodman & Renshaw 20th Annual Global Investment Conference on Wednesday, September 5, 2018 at 10:00 AM EDT in the Lotte New York Palace Hotel in...
- Aug 3, 2018
Pulmatrix, Inc. (NASDAQ: PULM) today reports its second quarter results. "We are pleased with the preliminary results of the three-part Phase 1/1b clinical trial of Pulmazole. The data supports...
- Jul 23, 2018Members include experts in both clinical research and management of Allergic Bronchopulmonary Aspergillosis and Asthma
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases announced today the formation of the...
- Jul 17, 2018Pulmatrix Announces Positive Top-Line Preliminary Results from Part 3 of the 3-Part Phase 1/1b Clinical Trial of Pulmazole - an Inhaled Dry-Powder iSPERSE™ Formulation of ItraconazoleSingle dose of Pulmazole safe and well tolerated in subjects with asthma
Pulmatrix, Inc. (NASDAQ: PULM) announced today that all dosing and follow up visits have been completed for Part 3 of the ongoing first-in-human study of Pulmazole (PUR1900) - an inhaled iSPERSETM...
- Jun 25, 2018All doses were well tolerated in normal healthy volunteers in Parts 1 and 2 at up to 35 mg of itraconazole, the maximal dose planned
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases announced today top-line results for the...
- Jun 13, 2018Data published in the British Journal of Clinical Pharmacology demonstrate that PUR0200 achieves similar improvements in lung function to Spiriva® HandiHaler® at significantly lower doses
Pulmatrix, Inc. (NASDAQ: PULM), a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases announced today the publication of data...
